NI201800096A - Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas - Google Patents

Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Info

Publication number
NI201800096A
NI201800096A NI201800096A NI201800096A NI201800096A NI 201800096 A NI201800096 A NI 201800096A NI 201800096 A NI201800096 A NI 201800096A NI 201800096 A NI201800096 A NI 201800096A NI 201800096 A NI201800096 A NI 201800096A
Authority
NI
Nicaragua
Prior art keywords
compositions
methods
stabilize
alphaviruses
alfavirus
Prior art date
Application number
NI201800096A
Other languages
English (en)
Inventor
Ann Livengood Jill
Duane Powell Timothy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of NI201800096A publication Critical patent/NI201800096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades aquí se refieren a las composiciones y métodos para estabilizar los alfavirus vivos. Otras modalidades se refieren a composiciones y métodos para reducir la degradación de alfavirus atenuados vivos. Ciertas modalidades se refieren a proporcionar una composición estabilizante mientras se reduce la reacción inmune en un sujeto a excipientes que estabilizan los alfavirus vivos proporcionando formulaciones mejoradas. Todavía otras modalidades se refieren a usos de composiciones descritas aquí en kits para aplicaciones portátiles y métodos en donde las composiciones reducen la degradación de los alfavirus vivos.
NI201800096A 2016-03-31 2018-09-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas NI201800096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
NI201800096A true NI201800096A (es) 2019-02-01

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800096A NI201800096A (es) 2016-03-31 2018-09-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Country Status (19)

Country Link
US (2) US10632184B2 (es)
EP (1) EP3436063A1 (es)
JP (1) JP2019513138A (es)
KR (1) KR20180135912A (es)
CN (1) CN109069614A (es)
AU (1) AU2017241590A1 (es)
BR (1) BR112018069035A2 (es)
CA (1) CA3019529A1 (es)
CO (1) CO2018010357A2 (es)
CR (1) CR20180456A (es)
DO (1) DOP2018000211A (es)
EC (1) ECSP18081486A (es)
MX (1) MX2018011837A (es)
NI (1) NI201800096A (es)
PE (1) PE20190149A1 (es)
PH (1) PH12018502119A1 (es)
SG (1) SG11201808458QA (es)
SV (1) SV2018005747A (es)
WO (1) WO2017172643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
CA3149932A1 (en) * 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
WO2021028406A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
BRPI0716145B1 (pt) 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014151855A1 (en) 2013-03-14 2014-09-25 Inviragen, Inc. Compositions and methods for live, attenuated alphavirus formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
JP2019513138A (ja) 2019-05-23
US20190111124A1 (en) 2019-04-18
AU2017241590A1 (en) 2018-10-11
DOP2018000211A (es) 2018-12-31
CA3019529A1 (en) 2017-10-05
CO2018010357A2 (es) 2019-05-21
BR112018069035A2 (pt) 2019-01-29
US20200306361A1 (en) 2020-10-01
KR20180135912A (ko) 2018-12-21
SG11201808458QA (en) 2018-10-30
MX2018011837A (es) 2019-02-13
SV2018005747A (es) 2019-03-28
EP3436063A1 (en) 2019-02-06
ECSP18081486A (es) 2019-01-31
US10632184B2 (en) 2020-04-28
CR20180456A (es) 2019-01-09
PH12018502119A1 (en) 2019-07-15
WO2017172643A1 (en) 2017-10-05
CN109069614A (zh) 2018-12-21
PE20190149A1 (es) 2019-01-22

Similar Documents

Publication Publication Date Title
CL2018000162A1 (es) Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera
CL2019002346A1 (es) Inmunoconjugados de un anticuerpo anti-pd-1 con una il-2 o il-5 mutante.
CL2019000473A1 (es) Compuestos de pirrolizina sustituida y usos de los mismos.
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
ECSP18003879A (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2015002675A1 (es) Composiciones de arnm de cftr y métodos y usos relacionados
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
ECSP18081486A (es) Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas
UY35651A (es) Pirazolpiridinas sustituidas
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
AR105894A1 (es) Composición para aplicación tópica que comprende dimetil isosorbida, un poliol, y un antioxidante fenólico o polifenólico
MX2019000177A (es) Formulaciones de anticuerpos.
AR102376A1 (es) Método de tratamiento para anti-brote de tubérculos con cantidad reducida de cipc
CR20150553A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
UY35823A (es) Profármacos de antagonista de nmda